耐利福平结核暴露青少年左氧氟沙星预防性治疗剂量推导
研究利用已建立的儿童左氧氟沙星群体药代动力学模型,模拟0-19岁耐多药/利福平耐药结核暴露人群使用100mg分散片和250mg片剂的剂量方案。按体重带制定的方案使剂量分别达8-33 mg/kg和10-42 mg/kg,达到成人目标暴露水平,已纳入WHO指南。
要点
- WHO基于两项随机对照试验,推荐左氧氟沙星用于所有年龄耐多药/利福平耐药结核暴露者的预防性治疗。
- 模拟得出0-19岁按体重带给药方案:100mg分散片8-33 mg/kg,250mg片剂10-42 mg/kg。
- 该剂量方案达到成人目标暴露水平,已纳入WHO指南。
核心结论
- 按体重带给予左氧氟沙星可为0-19岁耐多药/利福平耐药结核暴露者提供达到成人目标暴露水平的预防性治疗剂量。
研究设计与样本
- 应用既往建立的0.2-16.8岁儿童左氧氟沙星群体药代动力学模型,结合WHO统一体重带和最高耐药结核发病率国家的人口学数据进行模拟。
主要发现
- 制定了0-19岁耐多药/利福平耐药结核暴露者左氧氟沙星预防性治疗的按体重带给药方案。
- 100mg分散片剂量对应8-33 mg/kg,250mg片剂剂量对应10-42 mg/kg。
- 上述剂量达到成人目标暴露水平。
关键数值与推荐
- WHO于2024年2月基于两项随机对照试验数据,强烈推荐左氧氟沙星作为所有年龄耐多药/利福平耐药结核暴露者的预防性治疗选择。
- 100mg分散片按体重带剂量为8-33 mg/kg。
- 250mg片剂按体重带剂量为10-42 mg/kg。
临床怎么用
- 临床可依据体重带选择左氧氟沙星剂型(100mg分散片或250mg片剂)为0-19岁耐多药/利福平耐药结核暴露者开展预防性治疗。
- 该体重带剂量策略已纳入WHO指南,有助于简化耐多药/利福平耐药结核预防性治疗的给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) is the leading single bacterial cause of death worldwide. In 2023, approximately 400 000 people developed multidrug- and rifampicin-resistant TB (MDR/RR-TB), which complicates treatment. TB preventive treatment (TPT) is a critical strategy to prevent the progression from TB infection to TB disease among those at risk. In February 2024, based on data from 2 randomized controlled trials, levofloxacin was strongly recommended by the World Health Organization (WHO) as a TPT option in people of all ages exposed to MDR/RR-TB. There are uncertainties about the optimal dosing of levofloxacin in children and adolescents when using dispersible and solid formulations. We used pharmacokinetic modeling and simulations to determine the best dosing strategy in people aged up to 19 years for both formulations of levofloxacin. METHODS: A previously developed population pharmacokinetic model of levofloxacin in children (0.2-16.8 years) was used and applied to new WHO harmonized weight bands. Simulations were conducted using demographic data from countries with the highest incidence of RR- or MDR-TB. Two currently available levofloxacin formulations (100 mg pediatric, dispersible tablets and 250 mg solid tablets) were considered. RESULTS: A dosing regimen by weight band was developed for levofloxacin when used as TPT in people aged 0-19 years exposed to MDR/RR-TB. Doses correspond to 8-33 mg/kg for the 100 mg dispersible tablets and 10-42 mg/kg for 250 mg solid tablets. These doses achieve adequate adult target exposure levels. CONCLUSIONS: Pragmatic, weight-band dosing strategies help simplify the administration of MDR/RR-TB TPT and have been included in WHO guidance.
引用
- Solans BP, Miyakawa R, Shin M, et al. Deriving Dosages for Levofloxacin Tuberculosis Preventive Treatment for Young People Exposed to Rifampicin-Resistant Tuberculosis. J Infect Dis. 2025. PMID: 40794705. doi:10.1093/infdis/jiaf401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。